The stock of Alimera Sciences Incorporated (NASDAQ:ALIM) registered a decrease of 38.05% in short interest. ALIM’s total short interest was 1.10 million shares in September as published by FINRA. Its down 38.05% from 1.78 million shares, reported previously. With 424,500 shares average volume, it will take short sellers 3 days to cover their ALIM’s short positions. The short interest to Alimera Sciences Incorporated’s float is 3.74%. The stock decreased 1.32% or $0.02 on September 13, hitting $1.49. About 153,298 shares traded hands. Alimera Sciences Inc (NASDAQ:ALIM) has declined 30.41% since February 8, 2016 and is downtrending. It has underperformed by 46.90% the S&P500.
Alimera Sciences, Inc. is a pharmaceutical company. The company has a market cap of $94.43 million. The Firm is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. It currently has negative earnings. The Firm operates through two divisions: U.S. and International.
The institutional sentiment decreased to 0.52 in Q2 2016. Its down 0.07, from 0.59 in 2016Q1. The ratio dropped, as 14 funds sold all Alimera Sciences Inc shares owned while 19 reduced positions. 10 funds bought stakes while 7 increased positions. They now own 20.32 million shares or 19.64% less from 25.29 million shares in 2016Q1.
North Run Capital Lp holds 0.71% of its portfolio in Alimera Sciences Inc for 3.50 million shares. Acuta Capital Partners Llc owns 974,318 shares or 0.58% of their US portfolio. Moreover, Deerfield Management Co has 0.28% invested in the company for 5.88 million shares. The California-based Palo Alto Investors Llc has invested 0.28% in the stock. J. Goldman & Co Lp, a New York-based fund reported 2.10 million shares.
Out of 2 analysts covering Alimera Sciences Inc (NASDAQ:ALIM), 1 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 50% are positive. Alimera Sciences Inc has been the topic of 2 analyst reports since January 19, 2016 according to StockzIntelligence Inc. Cowen & Co downgraded the stock on May 6 to “Market Perform” rating.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.